Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. ($BCAX), sold about $2.05 million in company shares across 16 open market transactions over the last 365 days, with the most recent on March 3, 2026. These sales rank 3,449th among 11,678 individual insiders in our database, where the average is $8.6 million across about 6.4 transactions per insider. Cohlhepp made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 16, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 8000 | $3.79 | 213,141.0000 | 54,563,864 | 3.90% | 0.01% |
| March 16, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 8000 | $19.66 | 205,141.0000 | 54,563,864 | 3.75% | 0.01% |
| March 16, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 4500 | $19.66 | 200,641.0000 | 54,563,864 | 2.19% | 0.01% |
| March 16, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 8000 | $0.00 | 117,334.0000 | 54,563,864 | 6.38% | 0.01% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 12892 | $0.00 | 125,334.0000 | 54,563,864 | 9.33% | 0.02% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 12892 | $3.79 | 222,533.0000 | 54,563,864 | 6.15% | 0.02% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 12892 | $18.16 | 209,641.0000 | 54,563,864 | 5.79% | 0.02% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 4500 | $18.16 | 205,141.0000 | 54,563,864 | 2.15% | 0.01% |
| Feb. 25, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 3108 | $3.79 | 213,272.0000 | 54,563,864 | 1.48% | 0.01% |
| Feb. 25, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 3108 | $18.04 | 210,164.0000 | 54,563,864 | 1.46% | 0.01% |
| Feb. 25, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 523 | $18.04 | 209,641.0000 | 54,563,864 | 0.25% | 0.00% |
| Feb. 25, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 3108 | $0.00 | 138,226.0000 | 54,563,864 | 2.20% | 0.01% |
| Feb. 2, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | A | Stock Option (Right to Buy) | 300000 | $0.00 | 300,000.0000 | 54,563,864 | 9999.99% | 0.55% |
| Jan. 22, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 3828 | $18.10 | 210,164.0000 | 54,563,864 | 1.79% | 0.01% |
| Jan. 15, 2026 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 149 | $18.02 | 213,992.0000 | 54,563,864 | 0.07% | 0.00% |
| Dec. 26, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 25000 | $0.00 | 39,909.0000 | 54,563,864 | 38.52% | 0.05% |
| Dec. 26, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 25000 | $4.44 | 214,141.0000 | 54,563,864 | 13.22% | 0.05% |
| Dec. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 8000 | $18.68 | 193,641.0000 | 54,563,864 | 3.97% | 0.01% |
| Dec. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 4500 | $18.68 | 189,141.0000 | 54,563,864 | 2.32% | 0.01% |
| Dec. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 8000 | $0.00 | 141,334.0000 | 54,563,864 | 5.36% | 0.01% |
| Dec. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 8000 | $3.79 | 201,641.0000 | 54,563,864 | 4.13% | 0.01% |
| Nov. 21, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 8000 | $3.79 | 206,141.0000 | 54,563,864 | 4.04% | 0.01% |
| Nov. 21, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 4500 | $18.05 | 193,641.0000 | 54,563,864 | 2.27% | 0.01% |
| Nov. 21, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 8000 | $0.00 | 149,334.0000 | 54,563,864 | 5.08% | 0.01% |
| Nov. 21, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 8000 | $18.05 | 198,141.0000 | 54,563,864 | 3.88% | 0.01% |
| Oct. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 8000 | $3.79 | 210,641.0000 | 54,563,864 | 3.95% | 0.01% |
| Oct. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 4500 | $18.16 | 198,141.0000 | 54,563,864 | 2.22% | 0.01% |
| Oct. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 8000 | $0.00 | 157,334.0000 | 54,563,864 | 4.84% | 0.01% |
| Oct. 15, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 8000 | $18.16 | 202,641.0000 | 54,563,864 | 3.80% | 0.01% |
| Oct. 7, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 8000 | $3.79 | 213,541.0000 | 54,563,864 | 3.89% | 0.01% |
| Oct. 7, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 2900 | $18.06 | 202,641.0000 | 54,563,864 | 1.41% | 0.01% |
| Oct. 6, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 24000 | $0.00 | 173,334.0000 | 54,563,864 | 12.16% | 0.04% |
| Oct. 7, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Stock Option (Right to Buy) | 8000 | $0.00 | 165,334.0000 | 54,563,864 | 4.62% | 0.01% |
| Oct. 6, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | M | Common Stock | 24000 | $3.79 | 245,141.0000 | 54,563,864 | 10.85% | 0.04% |
| Oct. 6, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 24000 | $18.06 | 221,141.0000 | 54,563,864 | 9.79% | 0.04% |
| Oct. 6, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 15600 | $18.06 | 205,541.0000 | 54,563,864 | 7.05% | 0.03% |
| Oct. 7, 2025 | Bicara Therapeutics Inc. | $BCAX | Cohlhepp Ryan | President and COO | S | Common Stock | 8000 | $18.06 | 205,541.0000 | 54,563,864 | 3.75% | 0.01% |